20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie.
Looking at options history for AbbVie (NYSE:ABBV) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 80% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $176,561 and 5, calls, for a total amount of $617,570.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $145.0 to $185.0 for AbbVie over the recent three months.
Analyzing Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's substantial trades, within a strike price spectrum from $145.0 to $185.0 over the preceding 30 days.
AbbVie 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | CALL | SWEEP | BEARISH | 01/17/25 | $34.3 | $34.0 | $34.0 | $145.00 | $340.0K | 10.4K | 102 |
| ABBV | CALL | TRADE | BEARISH | 06/21/24 | $4.5 | $4.3 | $4.3 | $180.00 | $150.5K | 3.7K | 359 |
| ABBV | CALL | TRADE | BEARISH | 08/16/24 | $5.3 | $5.2 | $5.2 | $185.00 | $52.0K | 956 | 0 |
| ABBV | PUT | SWEEP | BULLISH | 04/19/24 | $6.9 | $6.45 | $6.45 | $180.00 | $39.7K | 1.7K | 263 |
| ABBV | PUT | SWEEP | BULLISH | 05/17/24 | $8.7 | $8.5 | $8.57 | $180.00 | $38.5K | 548 | 72 |
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Having examined the options trading patterns of AbbVie, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Where Is AbbVie Standing Right Now?
- With a volume of 1,574,807, the price of ABBV is up 0.38% at $178.0.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 22 days.
Professional Analyst Ratings for AbbVie
In the last month, 2 experts released ratings on this stock with an average target price of $192.5.
- An analyst from Guggenheim persists with their Buy rating on AbbVie, maintaining a target price of $190.
- Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for AbbVie, targeting a price of $195.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AbbVie options trades with real-time alerts from Benzinga Pro.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!